相似文献
1
Assessment of treatment response in tuberculosis.
Expert Rev Respir Med. 2016 Jun;10(6):643-54. doi: 10.1586/17476348.2016.1166960. Epub 2016 Mar 31.
2
Failing a re-treatment regimen does not predict MDR/XDR tuberculosis: is "blind" treatment dangerous?
Eur Respir J. 2011 May;37(5):1283-5. doi: 10.1183/09031936.00144710.
3
[The clinical features of tuberculosis in children and adolescents excreting drug-resistant Mycobacterium tuberculosis strains].
Probl Tuberk Bolezn Legk. 2009(6):13-6.
4
Treat the patient, not the result.
S Afr Med J. 2009 Jun;99(6):412.
5
[Multidrug-resistant tuberculosis in Romania].
Pneumoftiziologia. 1997 Jul-Sep;46(3):161-78.
6
Correlates of treatment outcomes and drug resistance among pulmonary tuberculosis patients attending tertiary care hospitals of Kolkata, India.
PLoS One. 2014 Oct 7;9(10):e109563. doi: 10.1371/journal.pone.0109563. eCollection 2014.
7
[Molecular diagnosis of Mycobacterium tuberculosis complex resistant to isoniazid and rifampicin in Burkina Faso].
Pan Afr Med J. 2015 May 29;21:73. doi: 10.11604/pamj.2015.21.73.5494. eCollection 2015.
8
Modalities to monitor the treatment response in tuberculosis.
Indian J Tuberc. 2018 Apr;65(2):109-117. doi: 10.1016/j.ijtb.2017.12.014. Epub 2018 Jan 8.
9
Summaries for patients. Treatment outcomes for patients with multidrug-resistant tuberculosis.
Ann Intern Med. 2006 May 2;144(9):I18. doi: 10.7326/0003-4819-144-9-200605020-00002.
10
Recurrence after successful treatment among patients with multidrug-resistant tuberculosis.
Int J Tuberc Lung Dis. 2011 Oct;15(10):1331-3. doi: 10.5588/ijtld.11.0098.
引用本文的文献
1
Blood and urine early treatment response biomarkers in HIV-associated disseminated tuberculosis.
South Afr J HIV Med. 2025 Apr 9;26(1):1664. doi: 10.4102/sajhivmed.v26i1.1664. eCollection 2025.
2
Performance evaluation of alternative bacteriological measures of response to MDR-TB therapy during the initial 16 weeks of treatment.
Res Sq. 2025 Apr 10:rs.3.rs-5834681. doi: 10.21203/rs.3.rs-5834681/v1.
3
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.
J Antimicrob Chemother. 2025 May 2;80(5):1315-1323. doi: 10.1093/jac/dkaf076.
4
Continuous digital cough monitoring during 6-month pulmonary tuberculosis treatment.
ERJ Open Res. 2025 Mar 24;11(2). doi: 10.1183/23120541.00655-2024. eCollection 2025 Mar.
5
CXCL9/CXCL10 as biomarkers the monitoring of treatment responses in Pulmonary TB patients: a systematic review and meta-analysis.
BMC Infect Dis. 2024 Sep 27;24(1):1037. doi: 10.1186/s12879-024-09939-0.
6
Development and preliminary evaluation toward a new tuberculosis treatment monitoring tool: the PATHFAST TB LAM Ag assay.
J Clin Microbiol. 2024 Aug 14;62(8):e0062924. doi: 10.1128/jcm.00629-24. Epub 2024 Jul 19.
7
A longitudinal prospective study of active tuberculosis in a Western Europe setting: insights and findings.
Infection. 2024 Apr;52(2):611-623. doi: 10.1007/s15010-024-02184-2. Epub 2024 Feb 13.
8
Inflammatory immune profiles associated with disease severity in pulmonary tuberculosis patients with moderate to severe clinical TB or anemia.
Front Immunol. 2023 Dec 12;14:1296501. doi: 10.3389/fimmu.2023.1296501. eCollection 2023.
9
Derivation of a high-resolution CT-based, semi-automated radiographic score in tuberculosis and its relationship to bacillary load and antitubercular therapy.
Eur Respir J. 2023 Sep 21;62(3). doi: 10.1183/13993003.00600-2023. Print 2023 Sep.
10
Chitinase and indoleamine 2, 3-dioxygenase are prognostic biomarkers for unfavorable treatment outcomes in pulmonary tuberculosis.
Front Immunol. 2023 Feb 6;14:1093640. doi: 10.3389/fimmu.2023.1093640. eCollection 2023.
本文引用的文献
1
Immune response gene polymorphisms in tuberculosis.
Acta Biochim Pol. 2015;62(4):633-40. doi: 10.18388/abp.2015_1130. Epub 2015 Dec 1.
2
In silico evaluation and exploration of antibiotic tuberculosis treatment regimens.
BMC Syst Biol. 2015 Nov 14;9:79. doi: 10.1186/s12918-015-0221-8.
3
Interferon gamma release assays for monitoring the response to treatment for tuberculosis: A systematic review.
Tuberculosis (Edinb). 2015 Dec;95(6):639-650. doi: 10.1016/j.tube.2015.07.002. Epub 2015 Jul 30.
4
Evaluation of a radiological severity score to predict treatment outcome in adults with pulmonary tuberculosis.
Int J Tuberc Lung Dis. 2015 Nov;19(11):1354-60. doi: 10.5588/ijtld.15.0098.
5
A Blueprint to Address Research Gaps in the Development of Biomarkers for Pediatric Tuberculosis.
Clin Infect Dis. 2015 Oct 15;61Suppl 3(Suppl 3):S164-72. doi: 10.1093/cid/civ613.
6
Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis.
Clin Infect Dis. 2015 Oct 15;61Suppl 3:S160-3. doi: 10.1093/cid/civ612.
7
Excessive Cytolytic Responses Predict Tuberculosis Relapse After Apparently Successful Treatment.
J Infect Dis. 2016 Feb 1;213(3):485-95. doi: 10.1093/infdis/jiv447. Epub 2015 Sep 7.
8
The association between sterilizing activity and drug distribution into tuberculosis lesions.
Nat Med. 2015 Oct;21(10):1223-7. doi: 10.1038/nm.3937. Epub 2015 Sep 7.
9
Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments.
Tuberculosis (Edinb). 2015 Dec;95(6):770-779. doi: 10.1016/j.tube.2015.08.001. Epub 2015 Aug 13.
10
Heme Oxygenase-1 Regulation of Matrix Metalloproteinase-1 Expression Underlies Distinct Disease Profiles in Tuberculosis.
J Immunol. 2015 Sep 15;195(6):2763-73. doi: 10.4049/jimmunol.1500942. Epub 2015 Aug 12.
Zotero 插件